Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy

被引：25

作者：

Baker, Gabrielle M. ^{[1
,2
]}

King, Tari A. ^{[3
,5
]}

Schnitt, Stuart J. ^{[4
,5
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA

[2] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dept Surg Surg Oncol, 75 Francis St, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

ADVANCES IN ANATOMIC PATHOLOGY | 2019年 / 26卷 / 04期

关键词：

neoadjuvant systemic therapy; breast cancer; pathologic assessment; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; INTERNATIONAL EXPERT CONSENSUS; CARCINOMA IN-SITU; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; RESIDUAL DISEASE; FREE SURVIVAL; INDUCTION CHEMOTHERAPY;

D O I：

10.1097/PAP.0000000000000237

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Breast and axillary lymph node specimens from breast cancer patients treated with neoadjuvant systemic therapy are being encountered by pathologists with increasing frequency. Evaluation of these specimens presents challenges that differ from those encountered during the examination of other types of breast specimens. This article reviews the key issues regarding the gross and microscopic evaluation of post-neoadjuvant systemic therapy breast and lymph node specimens, and emphasizes the importance of accurate specimen evaluation in assessing treatment response.

引用

页码：221 / 234

页数：14

共 125 条

[1] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[2] Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer [J].

Ali, H. Raza ;

Dariush, Aliakbar ;

Provenzano, Elena ;

Bardwell, Helen ;

Abraham, Jean E. ;

Iddawela, Mahesh ;

Vallier, Anne-Laure ;

Hiller, Louise ;

Dunn, Janet. A. ;

Bowden, Sarah J. ;

Hickish, Tamas ;

McAdam, Karen ;

Houston, Stephen ;

Irwin, Mike J. ;

Pharoah, Paul D. P. ;

Brenton, James D. ;

Walton, Nicholas A. ;

Earl, Helena M. ;

Caldas, Carlos .

BREAST CANCER RESEARCH, 2016, 18

[3]

[Anonymous], RES CANC BURD CALC A

[4] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Smith, RE ;

Geyer, CE ;

Mamounas, EP ;

Fisher, B ;

Brown, AM ;

Robidoux, A ;

Margolese, R ;

Kahlenberg, MS ;

Paik, S ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027

[5] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

[6] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].

BONADONNA, G ;

VERONESI, U ;

BRAMBILLA, C ;

FERRARI, L ;

LUINI, A ;

GRECO, M ;

BARTOLI, C ;

DEYOLDI, GC ;

ZUCALI, R ;

RILKE, F ;

ANDREOLA, S ;

SILVESTRINI, R ;

DIFRONZO, G ;

VALAGUSSA, P .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545

[7] Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].

Bonadonna, G ;

Valagussa, P ;

Brambilla, C ;

Ferrari, L ;

Moliterni, A ;

Terenziani, M ;

Zambetti, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100

[8] Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration [J].

Bossuyt, V. ;

Provenzano, E. ;

Symmans, W. F. ;

Boughey, J. C. ;

Coles, C. ;

Curigliano, G. ;

Dixon, J. M. ;

Esserman, L. J. ;

Fastner, G. ;

Kuehn, T. ;

Peintinger, F. ;

von Minckwitz, G. ;

White, J. ;

Yang, W. ;

Badve, S. ;

Denkert, C. ;

MacGrogan, G. ;

Penault-Llorca, F. ;

Viale, G. ;

Cameron, D. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1280-1291

[9] Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy [J].

Bossuyt, Veerle ;

Symmans, W. Fraser .

ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) :3153-3161

[10] Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer [J].

Boughey, Judy C. ;

Peintinger, Florentia ;

Meric-Bernstam, Funda ;

Perry, Allison C. ;

Hunt, Kelly K. ;

Babiera, Gildy V. ;

Singletary, S. E. ;

Bedrosian, Isabelle ;

Lucci, Anthony ;

Buzdar, Aman U. ;

Pusztai, Lajos ;

Kuerer, Henry M. .

ANNALS OF SURGERY, 2006, 244 (03) :464-470

← 1 2 3 4 5 6 7 8 9 10 →